Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Endothelial DamageDexmedetomidineSyndecan 1Heparan Sulpahate
Interventions
DRUG

Dexmedetomidine+propofol+remifentanyl group

The dexmedetomidine+TIVA group will receive a bolus of 0.8-1 µg/kg dexmedetomidine for 10 minutes followed by continuous dexmedetomidine infusion at a rate of 0.3-0.5 µg/kg/hour.

DRUG

propofol+remifentanyl group

propofol 5-8 mg/kg/h and remifentanil 5-10 µg/kg/h will be administered to all patients

Trial Locations (1)

23100

Firat University Hospital, Elâzığ

All Listed Sponsors
lead

Firat University

OTHER

NCT06897696 - Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers | Biotech Hunter | Biotech Hunter